Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis

Abstract

Despite higher incidence of grade 3/4 colitis, IFX added to CS for the treatment of patients with irEC was associated with a significantly shorter time to symptom resolution. The data suggest that early introduction of IFX should be considered for patients with irEC until definitive prospective clinical trials are conducted.